NJT Stock Overview
RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
RegenETP, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.22 |
| 52 Week High | US$0.99 |
| 52 Week Low | US$0.20 |
| Beta | 0.86 |
| 1 Month Change | 0% |
| 3 Month Change | 10.00% |
| 1 Year Change | -75.56% |
| 3 Year Change | -98.99% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| NJT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | -0.3% |
| 1Y | -75.6% | -19.9% | 2.8% |
Return vs Industry: NJT underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: NJT underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| NJT volatility | |
|---|---|
| NJT Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NJT's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NJT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 43 | Richard Hague | www.polarityte.com |
RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services.
RegenETP, Inc. Fundamentals Summary
| NJT fundamental statistics | |
|---|---|
| Market cap | €436.38k |
| Earnings (TTM) | -€7.75m |
| Revenue (TTM) | €68.13k |
6.4x
P/S Ratio-0.1x
P/E RatioIs NJT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NJT income statement (TTM) | |
|---|---|
| Revenue | US$73.00k |
| Cost of Revenue | US$125.00k |
| Gross Profit | -US$52.00k |
| Other Expenses | US$8.25m |
| Earnings | -US$8.30m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15 |
| Gross Margin | -71.23% |
| Net Profit Margin | -11,376.71% |
| Debt/Equity Ratio | 0% |
How did NJT perform over the long term?
See historical performance and comparison